SAFER
GENE-EDITING
THERAPEUTICS


CRISPR-CAS (CAS9, CAS12, CAS13) AND ADENO-ASSOCIATED VIRUS (AAV) CURE HUMAN DISEASES.
THE PROBLEM: THEY CAUSE UNDESIRED IMMUNE RESPONSES THAT POSE SERIOUS DANGERS TO PATIENT SAFETY AND TREATMENT EFFICACY.


7TX

SEVEN THERAPEUTICS DEVELOPS IMMUNE-STEALTH GENE-EDITING THERAPEUTICS THAT EFFICACIOUSLY BYPASS HOST IMMUNE DEFENSES AND SAFELY CORRECT DISEASES.


Our Technology

Universal

Immune genes are exceptionally diverse among people, leading to individuals with different susceptibility towards protein drugs. Our therapeutics are precisely engineered to work despite each patient's unique immune profile and genetic background.

Platforms

We develop technological platforms that deimmunize broad classes of therapeutics.

Novel IP

New functionalities. Advanced engineering. Our new gene-editing modalities constitute novel composition of matter.

Impact

We engineer immune-silent and immune-stealth therapeutics to benefit human lives. Gene-editing can cure the root causes of many human diseases. In making these therapeutics safer for patients, we are realizing our vision of a world without diseases.

Our Team

Wei Leong Chew Co-founder

Prashant Mali Co-founder

George Church Scientific Advisor